Collegium Pharmaceutical, Inc. $COLL Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 23.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 639,694 shares of the specialty pharmaceutical company’s stock after selling 197,855 shares during the period. Emerald Advisers LLC owned 2.03% of Collegium Pharmaceutical worth $22,383,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. CWM LLC lifted its position in Collegium Pharmaceutical by 453.9% during the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 1,153 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 744.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after acquiring an additional 2,190 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Collegium Pharmaceutical by 368.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock valued at $82,000 after acquiring an additional 2,169 shares during the last quarter. NewEdge Advisors LLC grew its holdings in shares of Collegium Pharmaceutical by 304.6% in the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 2,294 shares during the period. Finally, EMC Capital Management purchased a new stake in shares of Collegium Pharmaceutical in the second quarter valued at about $97,000.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on COLL shares. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price (up from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday, January 9th. Weiss Ratings restated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a report on Monday, December 29th. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Truist Financial set a $55.00 price objective on Collegium Pharmaceutical in a research report on Wednesday, January 7th. Finally, Needham & Company LLC lifted their target price on Collegium Pharmaceutical from $48.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $52.80.

Collegium Pharmaceutical Stock Down 1.4%

NASDAQ:COLL opened at $47.01 on Thursday. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $50.79. The stock’s fifty day moving average is $47.20 and its two-hundred day moving average is $39.48. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of 29.20 and a beta of 0.60. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.89 by $0.36. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The firm had revenue of $209.36 million for the quarter, compared to the consensus estimate of $191.25 million. During the same quarter in the previous year, the business earned $1.61 EPS. The company’s quarterly revenue was down 18.9% compared to the same quarter last year. Research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insider Transactions at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 17,600 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the completion of the transaction, the executive vice president owned 103,613 shares of the company’s stock, valued at approximately $4,991,038.21. This trade represents a 14.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the transaction, the director owned 52,629 shares of the company’s stock, valued at $2,475,141.87. This trade represents a 6.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 51,250 shares of company stock valued at $2,235,352. 2.51% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.